Company Overview - Enhabit operates nationally across 34 states with approximately 10,600 employees[5] - As of June 30, 2025, Enhabit has 249 Home Health locations and 114 Hospice locations[6] - As of June 30, 2025, 108 Hospice locations are co-located with Home Health locations[7] Industry Trends and Advocacy - The 2028 Medicare skilled home health expenditures are projected to be approximately $41 billion[9] - The 2028 Medicare Hospice expenditures are projected to be approximately $32 billion[9] - Without home health access, mortality rate increases by 41%[19] - Without home health access, episodes with readmissions increase by 34%[19] - Without home health access, episodes with emergency room visits increase 16%[19] - Without home health access, total cost of care increases by approximately $2,500[19] Financial Performance and Debt Management - Home health non-Medicare admissions increased 5.2%[38] - Hospice average daily census grew 12.3% year over year[38] - Since Q1 2024, bank debt has been reduced by $70 million[39] - Leverage ratio decreased from Q4 2023, largely due to $75 million in bank debt reduction during this period[28]

Financial Performance - Total net service revenue increased by 2.1% year-over-year to $266.1 million in Q2 2025[20] - Hospice net service revenue increased significantly by 19.4% year-over-year to $60.2 million[20] - Net income attributable to Enhabit, Inc was $5.2 million, a substantial increase compared to a loss of $0.2 million in Q2 2024[19, 20] - Adjusted EBITDA increased by 6.7% year-over-year to $26.9 million, with an Adjusted EBITDA margin of 10.1%[19, 20] - Home health net service revenue decreased by 2.0% year-over-year to $205.9 million[19, 20] Operational Metrics - Home Health non-Medicare admissions increased by 5.2% year-over-year[18, 63] - Hospice average daily census (ADC) grew by 12.3% year-over-year[18, 40] - Home Health Medicare ADC decreased by 3.4% compared to a 14.1% decline in the corresponding 2024 period[28] Debt and Liquidity - Bank debt was reduced by $10.0 million in Q2 2025, and is $70.0 million lower than Q1 2024[19] - Total debt decreased from $515.4 million at the end of 2024 to $479.3 million as of June 30, 2025[53] - Available liquidity was $113.5 million as of June 30, 2025[53, 55] Guidance - Updated 2025 net service revenue guidance to $1.06 billion to $1.073 billion[56]

Core Insights - Enhabit reported a modest revenue increase and stronger-than-expected profitability in Q2 2025, with GAAP revenue of $266.1 million, exceeding analyst expectations of $263.4 million, and up from $260.6 million in the prior year [1][2] - Non-GAAP EPS was $0.13, beating the consensus estimate of $0.10 and up from $0.07 a year earlier, prompting management to raise full-year guidance for revenue, adjusted EBITDA, and adjusted EPS [1][2][12] Financial Performance - GAAP revenue increased by 2.1% year-over-year, while non-GAAP EPS rose by 85.7% [2] - Adjusted EBITDA was $26.9 million, up 6.7% from $25.2 million in Q2 2024, with an adjusted EBITDA margin of 10.1%, an increase of 0.4 percentage points [2] - Free cash flow (non-GAAP) increased by 28.2% to $10.9 million compared to $8.5 million in the prior year [2] Business Overview - Enhabit operates in 34 states, providing skilled home health and hospice care, with 249 home health and 114 hospice locations, making it one of the largest standalone operators in the sector [3] - The business model combines Medicare and non-Medicare payers, focusing on optimizing payer contracts and expanding value-based payment arrangements [4] Segment Performance - Home health segment revenue declined by 2.0% to $205.9 million, primarily due to a 4.7% drop in Medicare revenue, while non-Medicare home health revenue rose by 1.7% [5] - The hospice segment saw significant growth, with net service revenue increasing by 19.4% to $60.2 million, and adjusted EBITDA reaching $14.0 million, up 53.8% from the prior year [7] Strategic Initiatives - Enhabit opened three new locations and paid down $10.0 million in debt as part of a deleveraging plan [8] - The company is investing in predictive analytics and technology to enhance operational efficiency and patient outcomes [4][11] Outlook - Management raised FY2025 guidance for net service revenue to between $1.060 and $1.073 billion, adjusted EBITDA to $104 to $108 million, and adjusted EPS to a range of $0.47 to $0.55 [12] - Key factors to monitor include trends in home health Medicare volumes, payer contract negotiations, and the impact of technology on productivity and quality [13]

Core Viewpoint - The Pennant Group, Inc. is set to release its second quarter 2025 financial results on August 6, 2025, followed by a live webcast on August 7, 2025, where management will discuss these results [1][2]. Company Overview - The Pennant Group, Inc. operates as a holding company for independent subsidiaries that provide healthcare services, including home health, hospice, and senior living services across multiple states in the U.S. [4]. - The company's subsidiaries are independently managed, each with its own management, employees, and assets [4]. Investor Engagement - Investors are invited to participate in a live webcast on August 7, 2025, at 10:00 a.m. Mountain Time, to discuss the second quarter results [2]. - The webcast will be available for replay on the company's website until August 6, 2026 [3]. Contact Information - For further inquiries, the company can be contacted at (208) 401-1400 or via email at ir@pennantservices.com [5].

Core Viewpoint - Enhabit (EHAB) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The upgrade for Enhabit suggests an improvement in its underlying business, which could lead to increased stock prices as investors respond positively [5][10]. - For the fiscal year ending December 2025, Enhabit is expected to earn $0.44 per share, with the Zacks Consensus Estimate having increased by 18% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - Enhabit’s upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9][10].

Financial Data and Key Metrics Changes - In Q1 2025, consolidated net revenue was $259.9 million, reflecting a sequential increase of $1.7 million or 0.7% quarter over quarter, but a decrease of $2.5 million or 1% year over year [16] - Consolidated adjusted EBITDA was $26.6 million, an increase of $1.5 million or 6% sequentially, and up $1.3 million or 5.1% year over year, with an overall EBITDA margin of 10.2%, an increase of 60 basis points from the prior year [17] - The leverage ratio improved to 4.4 times, below the covenant of 4.5 times, allowing for better pricing under existing agreements and additional flexibility for acquisitions [22][24] Business Line Data and Key Metrics Changes - Home Health segment revenue was $200.6 million, a slight increase of $200,000 or 0.1%, with a 3.7% increase in average daily census [18] - Hospice segment revenue reached $59.3 million, reflecting a sequential increase of $1.5 million or 2.6% and a year-over-year increase of $10.1 million or 20.5% [19] - Home Health adjusted EBITDA totaled $38.3 million, reflecting a sequential increase of $2.8 million or 7.9% [18] Market Data and Key Metrics Changes - Non-Medicare admissions in Home Health were up 7.4% year over year, driven by payer innovation contracts [8] - Hospice admissions grew 8% year over year, with same-store growth of 5.2% [10] - Average daily census in hospice reached 38.09 in Q1, an improvement of 2.1% sequentially and 12.3% year over year [20] Company Strategy and Development Direction - The company is focusing on payer contract initiatives to drive growth, with a significant increase in the percentage of home health visits under payer innovation contracts from 30.8% to 44% [9] - A de novo strategy is being implemented, with one new hospice location opened and 13 projects underway [11] - The company aims to continue leveraging technology to improve efficiency and reduce costs, including piloting two internally developed apps [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to build capacity in a normalizing labor market, with a 4% increase in capacity from December to March [29] - The company reaffirmed its 2025 guidance based on strong Q1 results and business momentum [24] - Management noted that the focus remains on balancing admissions to maintain a healthy payer mix, especially in light of negative growth in Medicare [26] Other Important Information - The company completed the transition to outsourced coding resources, expected to deliver $1.5 million in cost savings for the remainder of 2025 [12] - Free cash flow generated in Q1 was approximately $17 million, with a 63.5% conversion rate [21] Q&A Session Summary Question: Thoughts on volume growth within the non-Medicare book of business - Management noted that payer innovation contracts contributed significantly to positive growth, with a focus on hiring to improve average daily census and admissions [26][27] Question: Expectations for labor market inflation - Management indicated a return to normal salary inflation rates of 2% to 3%, with some markets experiencing tighter conditions [28] Question: Initiatives for gaining share in hospice - Management highlighted the combination of increased referrals and the establishment of regional admissions departments to improve conversion rates [31][32] Question: Dynamics behind business per episode in home health - The use of the Metalogics Pulse tool has been critical in optimizing visits per episode, focusing on higher acuity patients [33][34] Question: Capacity and productivity in hospice - Management confirmed that they are maintaining capacity at the branch level and do not anticipate changes in growth trajectory [42][43] Question: Rate increases and inflation protection in payer contracts - Most contracts are two to three years long, with some having escalators tied to quality metrics, and management is actively renegotiating contracts [48][49] Question: Declining research rates - Management acknowledged challenges in securing research for patients, particularly as Medicare Advantage grows, but emphasized a focus on overall census growth [50][52]

Core Viewpoint - Enhabit (EHAB) is showing solid improvement in earnings estimates, which may lead to continued short-term price momentum and a positive earnings outlook [1][2]. Estimate Revisions - The upward trend in earnings estimate revisions reflects growing analyst optimism regarding Enhabit's earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, the earnings estimate is $0.07 per share, unchanged from the previous year, with a Zacks Consensus Estimate increase of 18.18% over the last 30 days due to one upward revision [4]. - For the full year, Enhabit is expected to earn $0.37 per share, representing a 76.19% increase from the prior year, with a 26.14% increase in consensus estimates driven by three upward revisions [5]. Zacks Rank - Enhabit currently holds a Zacks Rank 2 (Buy), indicating promising estimate revisions and a strong potential for outperformance compared to the S&P 500 [6]. - The Zacks Rank system has a proven track record, with Zacks 1 (Strong Buy) stocks averaging a +25% annual return since 2008 [3]. Stock Performance - Enhabit has experienced a 6.4% gain over the past four weeks, driven by solid estimate revisions, suggesting that its earnings growth prospects may lead to further stock price increases [7].